How Syngene is supporting clients in treating cancer using targeted protein degradation, protein stabilization approaches, and precision medicine therapies.

Challenges in developing PROTACs and critical questions that need to be addressed to move PROTAC molecules from Target to IND successfully.

How Syngene’s proprietary data platform is safely and efficiently reducing the time taken to produce mAbs from gene to GMP-grade clinical supply by several months.

How Syngene is driving behavioural change in responsible use of natural resources while researching new technology and opportunities to improve its sustainability performance continuously.

SQDECC is an industry-recognized model that enables the operational teams to get a unified view of their efficiency across parameters of Safety, Quality, Delivery, Engagement, Cost, and Compliance (SQDECC).

DoE is achieving increasing acceptance in the pharmaceutical sector as it is being seen as an efficient tool for process optimization, including helping to develop quality products.

The continuous flow chemistry processes established in the lab can now be readily transferred to the production facilities and scaled up for commercial use without substantially altering reaction conditions.

Understanding the concept behind determining UV RRF of non-isolated impurities using High Performance Liquid Chromatography and Nuclear Magnetic Resonance

Key considerations for developing protein degraders from a medicinal chemistry perspective regardless of the mechanism of modulation.